NCT02670408 Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
| NCT ID | NCT02670408 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Cardiac Transplant Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2016-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2016-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.
Eligibility Criteria
Inclusion Criteria: * biopsy for clinical indications Exclusion Criteria: * no consent * pregnant women
Contact & Investigator
Philip F Halloran, MD PhD
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT02670408 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Transplant Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02670408 currently recruiting?
Yes, NCT02670408 is actively recruiting participants. Contact the research team at konrad@ualberta.ca for enrollment information.
Where is the NCT02670408 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States, Dallas, United States, Salt Lake City, United States and 9 additional locations.
Who is sponsoring the NCT02670408 clinical trial?
NCT02670408 is sponsored by University of Alberta. The principal investigator is Philip F Halloran, MD PhD at University of Alberta. The trial plans to enroll 900 participants.